GenomicsScience Translational MedicinePeer-reviewed
Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in the activated B-cell subtype of diffuse large B-cell lymphoma
Neeraj Kumar Jain, Keenan T. Hartert, Saber Tadros…·Michael R. Green
The paper identifies TCF4 overexpression driven by 18q21.2 gains as a mechanism promoting IgM expression in ABC-like DLBCL and shows BET inhibitors can suppress it.
64 citationstop 2%